Get the Stockscreener App
0.2801
18.88%
-0.0652
After Hours:
.28
-0.000100
-0.04%
Aptevo Therapeutics Inc stock is traded at $0.2801, with a volume of 2.66M.
It is down -18.88% in the last 24 hours and down -7.86% over the past month.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$0.3453
Open:
$0.3356
24h Volume:
2.66M
Relative Volume:
0.40
Market Cap:
$5.19M
Revenue:
$12.99M
Net Income/Loss:
$-23.72M
P/E Ratio:
-0.0851
EPS:
-3.29
Net Cash Flow:
$-23.28M
1W Performance:
-8.97%
1M Performance:
-7.86%
6M Performance:
-61.63%
1Y Performance:
-96.81%
1-Day Range:
$0.28
$0.3453
1-Week Range:
$0.28
$0.3592
52-Week Range:
$0.138
$10.80
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
0.2801 | 5.19M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
Aptevo Therapeutics announces 1-for-37 reverse stock split By Investing.com - Investing.com Nigeria
What's Going On With Aptevo Therapeutics Shares Friday? - Benzinga
Aptevo Therapeutics Announces 1-for-37 Reverse Stock Split - Marketscreener.com
Aptevo Therapeutics announces 1-for-37 reverse stock split - Investing.com
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan - AccessWire
Aptevo Therapeutics Announces 37-to-1 Reverse Split to Meet Nasdaq Requirements | APVO Stock News - StockTitan
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation - AccessWire
Aptevo to Showcase Cancer Therapy Platform at Major Healthcare Conference | APVO Stock News - StockTitan
Does Aptevo Therapeutics Inc (NASDAQ: APVO) Still Look Hot This Week? - Stocks Register
Aptevo reports progress in cancer antibody trials By Investing.com - Investing.com Australia
Aptevo reports progress in cancer antibody trials - Investing.com India
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm - AccessWire
Aptevo's Cancer Drug Shows 90% Blast Reduction in AML Trial, Pipeline Advances | APVO Stock News - StockTitan
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies - AccessWire
Aptevo's AML Drug Shows 90% Cancer Reduction in Early Trial Results | APVO Stock News - StockTitan
Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated at StockNews.com - Defense World
Armistice Capital, LLC's Strategic Acquisition of Aptevo Therape - GuruFocus.com
Alligator Bioscience reports positive results for APV-527 in Phase 1 study - Marketscreener.com
Alligator Bioscience announces positive results for APV-527 - Marketscreener.com
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial - AccessWire
Aptevo's Cancer Drug Shows Promise: 56% of Patients Achieve Disease Stability in Phase 1 | APVO Stock News - StockTitan
Hudson Bay Capital Management LP's Strategic Acquisition in Aptevo Therapeutics Inc - GuruFocus.com
Aptevo Therapeutics Inc (APVO) Quarterly 10-Q Report - Quartz
Aptevo Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update - AccessWire
Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated by Analysts at StockNews.com - Defense World
Alligator Bioscience to present positive data for mitazalimab at SITC - Marketscreener.com
Aptevo Therapeutics Inc (NASDAQ: APVO) Has Great Upside Potential - Stocks Register
Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com - Defense World
Alligator Bioscience presents positive interim data from Phase 1 study - Marketscreener.com
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024 - AccessWire
Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update - Defense World
Aptevo Therapeutics secures shareholder nod for key proposals By Investing.com - Investing.com South Africa
Aptevo Therapeutics secures shareholder nod for key proposals - Investing.com India
Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket(SAVE) - Benzinga
There is no doubt that Aptevo Therapeutics Inc (APVO) ticks all the boxes. - SETE News
Aptevo Therapeutics Inc (NASDAQ: APVO) – An Analysis Is What You Need - Stocks Register
Stock Market Recap: Aptevo Therapeutics Inc (APVO) Concludes at 0.15, a -2.87 Surge/Decline - The Dwinnex
A stock that deserves closer examination: Aptevo Therapeutics Inc (APVO) - US Post News
APVO stock plunges to 52-week low of $0.14 amid market challenges - Investing.com Australia
APVO stock plunges to 52-week low of $0.14 amid market challenges By Investing.com - Investing.com South Africa
You might want to take a look at Aptevo Therapeutics Inc (APVO) now - SETE News
APVO’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Gaining Ground: Aptevo Therapeutics Inc (APVO) Closes Lower at 0.16, Down -2.60 - The Dwinnex
Aptevo Therapeutics Inc (APVO) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Aptevo Therapeutics (NASDAQ:APVO) Research Coverage Started at StockNews.com - Defense World
Research Analysts’ Updated EPS Estimates for October 6th (APVO, CNP, FDX, FLNT, FRD, GALT, HOPE, KBR, LSXMK, NVGS) - Defense World
Aptevo Therapeutics Inc (APVO)’s stock decline to 0.16 per share - US Post News
APVO Stock Update: Aptevo Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Financial Metrics Check: Aptevo Therapeutics Inc (APVO)’s Ratios for Trailing Twelve Months - The Dwinnex
Certain Restricted Stock Units of Aptevo Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2024. - Marketscreener.com
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):